Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Obesity
Research
Turkish bank invests $39M in Harvard next-gen obesity antibodies
Once the antibodies are ready, a new biotech called Enlila will launch and may license them for clinical development.
Darren Incorvaia
Jun 16, 2025 1:07pm
South Korean biotech's GLP-1 scores MASH win, reduces weight
Jun 16, 2025 7:22am
Novo plots ph. 3 trials for next-gen obesity asset amycretin
Jun 13, 2025 10:35am
Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs
Jun 11, 2025 7:30am
Eli Lilly taps Camurus' tech to advance long-acting obesity meds
Jun 3, 2025 5:04pm
Regeneron pens $2B pact for Hansoh's potential rival to Zepbound
Jun 2, 2025 8:20am